Cargando…
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant
BACKGROUND: Weight loss is often difficult to achieve in individuals with type 2 diabetes and anti-obesity drugs are often advocated to support dietary intervention. Despite the extensive use of centrally acting anti-obesity drugs, there is little evidence of how they affect dietary composition. We...
Autores principales: | Heppenstall, Charlotte, Bunce, Susan, Smith, Jamie C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479018/ https://www.ncbi.nlm.nih.gov/pubmed/22824101 http://dx.doi.org/10.1186/1475-2891-11-50 |
Ejemplares similares
-
Effects of the cannabinoid CB(1) receptor antagonist rimonabant on distinct measures of impulsive behavior in rats
por: Pattij, Tommy, et al.
Publicado: (2007) -
CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats
por: Zhao, Li, et al.
Publicado: (2021) -
Context-dependent effects of the CB1 receptor antagonist rimonabant on morphine-induced behavioral sensitization in female mice
por: Marinho, Eduardo A. V., et al.
Publicado: (2023) -
CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats
por: Dou, Zhan-jun, et al.
Publicado: (2020) -
Hepatic targeting of the centrally active cannabinoid 1 receptor (CB(1)R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
por: Hirsch, Shira, et al.
Publicado: (2023)